Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dilaforette AB Announces the Appointment of Christina Herder

Published: Wednesday, January 22, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
Appointment of Christina Herder as new CEO.

Dilaforette AB has announced the appointment of Christina Herder as new CEO. Christina Herder, PhD, MBA, will bring over 20 years of experience in product development and business development from the pharmaceutical industry.

“We are delighted that Christina is joining Dilaforette. Her expertise and experience will help us take the company forward to successful outcomes in malaria and sickle cell disease. I look forward to working with her over the next years”, says Robin Wright, Chairman of Dilaforette.

Dilaforette is developing sevuparin, a proprietary polysaccharide-based drug, for treatment of hematological crisis in malaria as well as vaso-occlusive crisis in sickle cell disease.

“I am looking forward to lead Dilaforette and to develop sevuparin into new therapies for patients, with a large unmet medical need”, says Christina Herder.

Christina holds a PhD from Royal Institute of Technology in Stockholm, Sweden, and an MBA from Stockholm University. Christina Herder joins Dilaforette from Sobi, where she has been working within Corporate Development as well as previously heading up the Portfolio Management in R&D.

She brings over 20 years of experience from pharmaceutical product development from Pharmacia, Medicarb, Biovitrum and Sobi. She has also been board member of Akinion Pharmaceuticals AB, for five years.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dilaforette Receives Positive COMP Opinion
Positive opinion on orphan drug designation in the EU for sevuparin in sickle-cell disease.
Thursday, January 22, 2015
Dilaforette Presents Results from Exploratory Phase I/II Clinical Trial in Uncomplicated Malaria
Aim of the trial was to study sevuparin in adult patients with uncomplicated falciparum malaria.
Saturday, May 31, 2014
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!